Informações:
Falhas:
ID
44571
Descrição
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00537381
Link
https://clinicaltrials.gov/show/NCT00537381
Palavras-chave
Versões (3)
- 19/09/2018 19/09/2018 -
- 19/09/2018 19/09/2018 -
- 27/09/2021 27/09/2021 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
27 de setembro de 2021
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Prostatic Neoplasms NCT00537381
Eligibility Prostatic Neoplasms NCT00537381
- StudyEvent: Eligibility
Similar models
Eligibility Prostatic Neoplasms NCT00537381
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Prostate carcinoma
Item
confirmed cancer of the prostate
boolean
C0600139 (UMLS CUI [1])
Neoplasm Metastasis
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1])
Life Expectancy
Item
have a life expectancy greater than 12 weeks
boolean
C0023671 (UMLS CUI [1])
Major surgery
Item
have at least 4 weeks from previous major surgery to date of first study agent given
boolean
C0679637 (UMLS CUI [1])
Progressive Disease Hormone Refractory | Status post Orchiectomy | Status post Gonadotropin-Releasing Hormone Analog | Status post Antiandrogen therapy | Exclusion Criteria
Item
have progressive hormone-refractory disease after orchiectomy or gonadotropin-releasing hormone analog and/or antiandrogen treatment within 6 months prior to the first study agent administration exclusion criteria
boolean
C1335499 (UMLS CUI [1,1])
C0019932 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0029189 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C1518041 (UMLS CUI [3,2])
C0231290 (UMLS CUI [4,1])
C0279492 (UMLS CUI [4,2])
C0680251 (UMLS CUI [5])
C0019932 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0029189 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C1518041 (UMLS CUI [3,2])
C0231290 (UMLS CUI [4,1])
C0279492 (UMLS CUI [4,2])
C0680251 (UMLS CUI [5])
CNS metastases
Item
have known central nervous system metastases (cancerous tumors that have spread to the brain from somewhere else in the body)
boolean
C0686377 (UMLS CUI [1])
Systemic therapy Hormone refractory prostate cancer
Item
had prior systemic non-hormonal therapy for hormone refractory prostate cancer
boolean
C1515119 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,2])
HIV Seropositivity | Hepatitis B | Hepatitis C
Item
have known human immunodeficiency virus (hiv, a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person) seropositivity or known hepatitis b or c infection
boolean
C0019699 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Major surgery Planned
Item
have planned major surgery during the study
boolean
C0679637 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,2])
Non-Prescription Drugs Prostate carcinoma | Herbal therapy Prostate carcinoma
Item
have taken any over-the-counter (medicine that can be bought without a prescription) or herbal treatment for prostate cancer within 4 weeks prior to the first study treatment administration
boolean
C0013231 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0242388 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C0600139 (UMLS CUI [1,2])
C0242388 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])